June 2022
Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2022
"06/13/22
- Substantial Reductions in Key Hormones and Hormone Precursors Observed After 14 Days of Crinecerfont Treatment in Adolescents with Classic CAH
- Two Phase 3 Global Registrational Studies Currently Underway in Pediatric (2–17 years of age) and Adult (18 years of age and older) Patients with Classic CAH SAN DIEGO, June 13, 2022 -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new Phase 2 data on the use of crinecerfont in adolescent patients with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD), which demonstrated substantial reductions in adrenal androgens and androgen precursors. These data will be shared as an oral presentation by Ron S. Newfield, M.D., University of California, San Diego and Rady Children's Hospital, San Diego on June 13 from 11:00 a.m.–12:30 p.m. ET (Presentation #OR18) at ENDO 2022, the Endocrine Society's 104th annual meeting in Atlanta from June 11–14. The company also presented data highlighting patient preferences and treatment patterns in classic CAH in Hall A1 on Saturday, June 11."